Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2026—How and why gastric cancer scoring for HER2 positivity differs from breast cancer scoring was the topic of a CAP TODAY webinar early this year presented by Josef Rüschoff, MD, of Kassel, Germany.
June 2026—Instrumentation for all laboratory testing sites—large and small—was the roundtable topic on April 21 when representatives of Roche, Beckman Coulter, and Siemens Healthineers met online with Moira Larsen, MD, MBA, of MedStar, and Joe Baker of Baylor Scott & White. CAP TODAY publisher Bob McGonnagle led, with questions about, among other things, AI, testing consolidation, what laboratories expect of vendors, and what laboratories are willing to contribute to the partnership. “We’re happy to help figure out what the bugs are,” Baker says of new instrumentation.
June 2026—CAP TODAY publisher Bob McGonnagle spoke on March 12 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Jesse M. Young, PhD, medical director for TriCore Research Institute’s research and clinical trials department and director of point-of-care testing. Dr. Young is also clinical assistant professor at the University of New Mexico.
Bob McGonnagle: Dr. Young, tell us about TriCore and the laboratories you oversee.
Dr. Young (TriCore): TriCore Reference Laboratory is a full-service diagnostic laboratory. The core laboratory offers about 2,900 test codes and has a modality similar to that of Labcorp and Quest, but we’re focused on New Mexican populations. We serve most of the hospitals in the area and have statewide collection sites whereby we’re trying to expand health care and provide coverage for our communities so everyone in the state has access to health care near their home instead of having to drive six hours to the nearest collection site, drive home, and then be called back for a critical value. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ZeptoMetrix.
May 2026—When it comes to cancer mutations, there are big fish in little ponds, and little fish in big ponds, and big fish in big ponds, and little fish in little ponds. The ESR1 mutation and its emergence in advanced breast cancer is still deciding what stripe of fish it is—or rather, breast specialists, researchers, and the FDA are in the midst of figuring out potentially important uses …
May 2026—Two years after the Food and Drug Administration approved the first HPV self-collection devices, physicians and cervical cancer prevention advocates are debating the best use for the new screening option.
May 2026—In the laboratory general accreditation checklist in the 2025 edition, released last December, is new emphasis on a prospective risk assessment process in the laboratory’s quality management …
May 2026—Preserving tissue for molecular and other biomarker studies is top of mind for many, and in a CAP25 lung cancer session last fall, an approach to doing so was presented.
May 2026—Has your blood collection container been validated for the assays you have employed it for? At what point does a verification of a blood collection tube become a validation, and how is a laboratory supposed to know when this threshold has been crossed and what actions to take?
May 2026—Cystatin C has notable advantages over serum creatinine as a biomarker of kidney filtration: fewer nonglomerular filtration rate determinants, more accurate dosing of medications with narrow therapeutic windows for individuals with obesity or low muscle mass, and greater accuracy in determining eligibility for a kidney transplant or for a simultaneous liver-kidney or heart-kidney transplant.
May 2026—The fast-changing world of sequencing was the topic that a panel of pathologists and industry representatives dug into in a Feb. 27 online roundtable, led by CAP TODAY publisher Bob McGonnagle.
